MX389282B - Composiciones y métodos para tratar sinucleinopatías. - Google Patents

Composiciones y métodos para tratar sinucleinopatías.

Info

Publication number
MX389282B
MX389282B MX2019011505A MX2019011505A MX389282B MX 389282 B MX389282 B MX 389282B MX 2019011505 A MX2019011505 A MX 2019011505A MX 2019011505 A MX2019011505 A MX 2019011505A MX 389282 B MX389282 B MX 389282B
Authority
MX
Mexico
Prior art keywords
compositions
methods
propylamino
benzothiazole
tetrahydro
Prior art date
Application number
MX2019011505A
Other languages
English (en)
Inventor
Kathleen E Clarence-Smith
Thomas N Chase
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MX389282B publication Critical patent/MX389282B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe el uso de un antagonista de 5HT3, en combinación con una 6-propilamino-4,5,6,7-tetrahidro-1,3-benzotiazol-2-amina, para reducir los efectos adversos y facilitar el tratamiento neuroprotector. de un paciente que padece un trastorno sinucleinopático para permitir una dosis diaria terapéuticamente efectiva de 6-propilamino-4,5,6,7-tetrahidro-1,3-benzotiazol-2-amina sin los efectos adversos limitantes de la dosis causados por pramipexol cuando se administra solo.
MX2019011505A 2017-03-27 2018-03-26 Composiciones y métodos para tratar sinucleinopatías. MX389282B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477187P 2017-03-27 2017-03-27
US201762528228P 2017-07-03 2017-07-03
PCT/US2018/024344 WO2018183192A1 (en) 2017-03-27 2018-03-26 Compositions and methods for treating synucleinopathies

Publications (1)

Publication Number Publication Date
MX389282B true MX389282B (es) 2025-03-20

Family

ID=63676741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011505A MX389282B (es) 2017-03-27 2018-03-26 Composiciones y métodos para tratar sinucleinopatías.

Country Status (11)

Country Link
US (2) US10799484B2 (es)
EP (1) EP3600291A4 (es)
JP (2) JP7557939B2 (es)
KR (3) KR20250108755A (es)
CN (1) CN110662537A (es)
AU (2) AU2018243718A1 (es)
BR (1) BR112019020100A2 (es)
IL (1) IL269550B2 (es)
MX (1) MX389282B (es)
TW (1) TW201840312A (es)
WO (1) WO2018183192A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615024B1 (en) * 2017-04-24 2026-02-18 Alto Neuroscience, Inc. Compositions comprising pramipexole and a 5ht3 antagonist for use in treating depression
JP7158425B2 (ja) 2017-06-30 2022-10-21 チェイス セラピューティクス コーポレイション Ｎｋ－１アンタゴニスト組成物およびうつ病の処置における使用法
AU2019346543A1 (en) * 2018-09-25 2021-05-20 Chase Therapeutics Corporation Composition and use for the treatment of Parkinson's disease and related disorders
IL294408A (en) 2019-12-31 2022-08-01 Chase Therapeutics Corp Kinases as biomarkers for neurodegenerative conditions
TW202508599A (zh) * 2023-05-19 2025-03-01 南韓商尹諾衛醫藥有限公司 用於神經保護或治療α突觸核蛋白及/或神經發炎相關疾病的化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
CN1206989C (zh) * 2002-04-01 2005-06-22 浙江省医学科学院 用于减轻阿朴吗啡副作用的复方鼻腔给药制剂
WO2005089515A2 (en) 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
ES2334061T3 (es) 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).
US20090041844A1 (en) 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
PL2026803T3 (pl) * 2006-05-16 2012-05-31 Knopp Neurosciences Inc Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
JP2010526054A (ja) 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド 併用医薬組成物
ES2559859T3 (es) 2007-05-16 2016-02-16 The Brigham And Women's Hospital, Inc. Tratamiento de sinucleinopatías
WO2009109990A2 (en) * 2008-01-24 2009-09-11 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of pramipexole
US8877768B2 (en) 2009-09-18 2014-11-04 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
US8618063B2 (en) 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy
WO2010144535A1 (en) * 2009-06-10 2010-12-16 The University Of North Carolina At Chapel Hill Methods and compositions for the induction of hypothermia
WO2011143721A1 (en) 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
EA031156B1 (ru) 2010-12-16 2018-11-30 Суновион Фармасьютикалз Инк. Сублингвальные пленки
JP6095072B2 (ja) 2011-10-27 2017-03-15 プロテオテク, インコーポレイテッドProteoTech, Inc. アミロイド病およびシヌクレイノパチーの処置のためのカフェイン含有化合物および組成物
JOP20130213B1 (ar) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
EP2892514A4 (en) * 2012-09-05 2016-04-13 Chase Pharmaceuticals Corp Neurotropic Anticholinergic Composition and Method
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11318122B2 (en) 2017-04-13 2022-05-03 Chase Therapeutics Corporation Pharmaceutical combination and its use for treating synucleinopathties

Also Published As

Publication number Publication date
JP7557939B2 (ja) 2024-09-30
KR20230144123A (ko) 2023-10-13
CN110662537A (zh) 2020-01-07
CA3058395A1 (en) 2018-10-04
KR102623819B1 (ko) 2024-01-10
AU2018243718A1 (en) 2019-11-07
BR112019020100A2 (pt) 2020-05-05
EP3600291A1 (en) 2020-02-05
IL269550A (en) 2019-11-28
US11547700B2 (en) 2023-01-10
IL269550B1 (en) 2024-09-01
US10799484B2 (en) 2020-10-13
JP7711113B2 (ja) 2025-07-22
US20200397761A1 (en) 2020-12-24
WO2018183192A1 (en) 2018-10-04
EP3600291A4 (en) 2020-12-23
IL269550B2 (en) 2025-01-01
JP2020512390A (ja) 2020-04-23
JP2023071825A (ja) 2023-05-23
US20200016127A1 (en) 2020-01-16
AU2024204167A1 (en) 2024-07-11
TW201840312A (zh) 2018-11-16
KR20200014273A (ko) 2020-02-10
KR20250108755A (ko) 2025-07-15

Similar Documents

Publication Publication Date Title
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2017005875A (es) Metodos para tratar enfermedades oculares.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
EA201991650A1 (ru) Способы лечения неврологических расстройств
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
EP4324454A3 (en) Cross-linking agents and associated methods
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MD20170025A2 (ro) Tratamente terapeutice pe bază de anamorelin
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
PH12021550671A1 (en) Prodrugs of cgrp antagonists
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EP4461362A3 (en) Nk1-antagonist combination and method for treating synucleinopathies
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica